

Solution to the exercises day 8

Basic Statistics for health researchers 2021

22 November 2021

1 Exercise A: what to adjust on?

To obtain a formal argument, we will denote by Y the PET signal, by X the genetic factor(s), and by $Z = (Z_1, Z_2, Z_3)$ the age, scanner type, and radioactive dose. We can express the PET signal as a function of the covariate at baseline (t_0) and follow-up (t_1). Under a linear model, we have for a generic individual:

$$\begin{aligned}Y(t_0) &= \alpha(t_0) + \beta X + \gamma_1 Z_1(t_0) + \gamma_2 Z_2(t_0) + \gamma_3 Z_3(t_0) + \varepsilon(t_0) \\Y(t_1) &= \alpha(t_1) + \beta X + \gamma_1 Z_1(t_1) + \gamma_2 Z_2(t_1) + \gamma_3 Z_3(t_1) + \varepsilon(t_1)\end{aligned}$$

So the difference is:

$$\begin{aligned}Y(t_1) - Y(t_0) &= \alpha(t_1) - \alpha(t_0) + \gamma_1(Z_1(t_1) - Z_1(t_0)) + \gamma_2(Z_2(t_1) - Z_2(t_0)) + \gamma_3(Z_3(t_1) - Z_3(t_0)) \\&\quad + \varepsilon(t_1) - \varepsilon(t_0) \\&= \alpha^* + \gamma_1 \Delta Z_1 + \gamma_2 \Delta Z_2 + \gamma_3 \Delta Z_3 + \varepsilon^*\end{aligned}$$

where $\Delta Z = (\Delta Z_1, \Delta Z_2, \Delta Z_3)$ is the change in age, scanner type and radioactive dose between baseline and follow-up.

1. Genetic factors are time-independent covariate and will therefore affect in the same way the baseline and follow-up measurement. Their effect will therefore cancel out when computing the change score $Y(t_1) - Y(t_0)$ so there is no need to adjust for them.

Age is technically a time-varying covariate but its variation is small between baseline and follow-up and its effect on the change score could be neglected.

To test the treatment effect, we could do a two sample t-test comparing the change score of the two groups.

2. The variables scanner type and radioactive dose are time dependent and it is their difference between baseline and follow-up that we should adjust for (see the expression of $Y(t_1) - Y(t_0)$). We could test the treatment effect using a linear regression with the change score as an outcome, group, scanner type, and radioactive dose as regressors and extract the p-value corresponding to the group effect. Note that compared to a t-test, using `lm` in **R** will assume same

variance between treatment groups ¹.

In a randomized experiment, this would reduce the residual variance and would therefore lead to a gain in power. We can see that in the expression of $Y(t_1) - Y(t_0)$ as, without adjustment, the residual would be $\xi^* = \gamma_1\Delta Z_1 + \gamma_2\Delta Z_2 + \gamma_3\Delta Z_3 + \varepsilon^*$ instead of ε^* . Since ε^* is independent of Z , the variance of ξ is greater than the variance of ε^* .

In a non-randomized experiment this can lead to a gain in power as well as a reduction in bias, as it will remove any confounding effect from scanner type and radioactive dose (if their effect is linear).

3. Adjusting on post-randomized variables can bias the treatment effect, e.g. if the variable is a mediator of the treatment effect.

It is very unlikely to be the case here as the production of the radioactive tracer and the choice of the scanner are logistic/technical choices that should be independent of the treatment group. It could be a problem if, for instance, more depressed patients take (much more) time to get into scanner leading to a lower radioactive dose. If the treatment is effective against depression, we will see a larger PET signal in the treated group even if the treatment would not affect the brain serotonergic system.

¹this can be relaxed using `LMMstar::lmm` or `nlme::gls`

2 Exercise B: Analyzing a longitudinal study

1. The `str` function reveals the presence of missing values in the dataset. We can also visualize see them when looking at the first rows of the dataset:

```
head(armdW)
```

	subject	lesion	line0	visual0	visual4	visual12	visual24	visual52	treat.f	miss.pat
1	1	3	12	59	55	45	NA	NA	Active	--XX
2	2	1	13	65	70	65	65	55	Active	----
3	3	4	8	40	40	37	17	NA	Placebo	----X
4	4	2	13	67	64	64	64	68	Placebo	----
5	5	1	14	70	NA	NA	NA	NA	Active	XXXX
6	6	3	12	59	53	52	53	42	Active	----

The `miss.pat` variable indicates the missing data pattern: "-" for observed data and "X" for missing data. The `treat.f` contain the randomization group and not the treatment given at a patient at a given timepoint. Indeed at baseline none of the subjects are treated.

2. Using the wide format, we can compute a summary statistic (e.g. the mean) in each group at a specific timepoint using `tapply`. For instance:

```
tapply(X = armd.wide$visual0, ## values
      INDEX = armd.wide$treat.f, ## group
      FUN = mean, ## function to apply to values per group
      na.rm = TRUE) ## additional argument for FUN
```

```
Placebo Active
55.33613 54.57851
```

Alternatively we can apply the `summarize` function to the long format of the data to compute most of the summary statistics at once. We should add the argument `na.rm` to indicate the missing values should be removed when computing the summary statistics:

```
library(LMMstar)
armd.sum <- summarize(visual ~ week * treat.f, ## value ~ group
  data = armd.long, ## dataset
  na.rm = TRUE) ## additional argument
armd.sum
```

	outcome	week	treat.f	observed	missing	mean	sd	min	median	max
1	visual	0	Placebo	119	0	55.33613	15.00129	22	56.0	85
2	visual	4	Placebo	117	2	53.96581	15.90973	12	54.0	84
3	visual	12	Placebo	117	2	52.87179	17.20091	3	53.0	85
4	visual	24	Placebo	112	7	49.33036	18.51242	5	50.5	85
5	visual	52	Placebo	105	14	44.43810	18.53683	11	44.0	85
6	visual	0	Active	121	0	54.57851	14.82270	20	57.0	82
7	visual	4	Active	114	7	50.91228	15.81114	12	52.0	84
8	visual	12	Active	110	11	48.67273	17.47665	12	49.5	82
9	visual	24	Active	102	19	45.46078	18.08050	5	45.0	84
10	visual	52	Active	90	31	39.10000	18.40069	4	37.0	84

To compute the correlation per group, it is easier to use the wide format:

```
armd.visual <- armd.wide[,paste0("visual",c(0,4,12,24,52))]
cor(armd.visual, use = "pairwise")
```

	visual0	visual4	visual12	visual24	visual52
visual0	1.0000000	0.8543813	0.7442610	0.6611932	0.5593174
visual4	0.8543813	1.0000000	0.8425869	0.7387614	0.6135206
visual12	0.7442610	0.8425869	1.0000000	0.8220768	0.7021200
visual24	0.6611932	0.7387614	0.8220768	1.0000000	0.8355586
visual52	0.5593174	0.6135206	0.7021200	0.8355586	1.0000000

We could also compute the correlation within group, e.g.:

```
cor(armd.visual[armd.wide$treat.f=="Active",], use = "pairwise")
```

	visual0	visual4	visual12	visual24	visual52
visual0	1.0000000	0.8331308	0.7527332	0.6446344	0.5842411
visual4	0.8331308	1.0000000	0.8500741	0.7490043	0.6228478
visual12	0.7527332	0.8500741	1.0000000	0.8711227	0.7253615
visual24	0.6446344	0.7490043	0.8711227	1.0000000	0.8279954
visual52	0.5842411	0.6228478	0.7253615	0.8279954	1.0000000

3. A boxplot of the data can be obtained using the `boxplot` function or the geometry `geom_boxplot` from the `ggplot2` package:

```
library(ggplot2)
gg.box <- ggplot(armd.long, aes(x = week, y = visual, fill = treat.f))
gg.box <- gg.box + geom_boxplot()
gg.box
```

A spaghetti plot can be obtained using the `matplot` function or the geometry `geom_line` and `geom_point()` from the `ggplot2` package:

```
gg.spa <- ggplot(armd.long, aes(x = week, y = visual,
  group = subject, color = treat.f))
gg.spa <- gg.spa + geom_point() + geom_line()
gg.spa
```

The mean plot is similar to a spaghetti plot except it is performed on the (previously computed) summary statistics instead of the original data:

```
gg.mean <- ggplot(armd.sum, aes(x = week, y = mean,
  group = treat.f, color = treat.f))
gg.mean <- gg.mean + geom_point() + geom_line() + ylab("visual")
gg.mean
```

It is possible to combine plots by defining several layers for the graph. Each layer has a specific geometry and dataset. Transparency (argument `alpha`) is used to focus the graph on the mean instead of the individual trajectories:

```
gg.spa2 <- ggplot(mapping = aes(x = week, color = treat.f))
gg.spa2 <- gg.spa2 + geom_line(data = armd.long, alpha = 0.3,
  aes(y = visual, group=subject))
gg.spa2 <- gg.spa2 + geom_point(data = armd.sum, aes(y = mean), size = 3)
gg.spa2 <- gg.spa2 + geom_line(data = armd.sum, aes(y = mean, group =
  treat.f), size = 1.5)
gg.spa2
```

A boxplot gives a very concise and readable representation of the data, even when with many timepoints and with a large number of observations. One can quickly identify trends in mean and variance over repetitions. One may also be able to identify certain deviation to normality (e.g. asymmetry). It, however, does give any information about the correlation between measurements. So in some sense it may exaggerate the variability. It is also not well suited to identify subgroups (e.g. half of the people respond to the treatment and the other half do not).

Spaghetti plots are well suited when there is an ordering of the repetitions (e.g. over time, this is not the case when looking at several brain regions though). They can be used to visually assess the correlation over time and detect groups of observations (e.g. some go up and some go down). However when the sample increase, they become hard to read and one should consider displaying subsets of the observations. We could have also used a scatterplot of visual at week 52 vs week 0. It gives the full picture of the data when having only 2 measurements but becomes hard to read with more timepoints as there are many pairs of variables.

4. We compute the percentage of missing value at a specific timepoint using the wide format, e.g:

```
100*tapply(is.na(armd.wide$visual52), armd.wide$treat.f, mean)
```

```
Placebo    Active  
11.76471 25.61983
```

For the graphical display, we would need to repeat the operation at the various timepoints and gather the results. Instead of doing that, we can reuse the `armd.sum` object, as the percentage of missing values can be deduced from the number of observed and missing values:

```
armd.sum$pc.missing <- armd.sum$missing/(armd.sum$observed+armd.sum$  
  missing)  
armd.sum[,c("week", "treat.f", "pc.missing")]
```

```
   week treat.f pc.missing  
1     0 Placebo 0.00000000  
2     4 Placebo 0.01680672  
3    12 Placebo 0.01680672  
4    24 Placebo 0.05882353  
5    52 Placebo 0.11764706  
6     0  Active 0.00000000  
7     4  Active 0.05785124  
8    12  Active 0.09090909  
9    24  Active 0.15702479  
10   52  Active 0.25619835
```

We can then use:

```
gg.mis <- ggplot(armd.sum, aes(x=week, y=pc.missing, group=treat.f, color=  
  treat.f))  
gg.mis <- gg.mis + geom_point(size = 3) + geom_line(, size = 1.25)  
gg.mis <- gg.mis + ylab("Percentage of missing data") + scale_y_continuous  
  (labels = scales::percent)  
gg.mis ## same as figure on slide 16
```

The number of missing values seems to increase over time, especially in the active group. In a real analysis, this would be concerning. Indeed, if patients with bad vision are more likely to drop out the mean computed at the later timepoints will be biased and not in a conservative way. It could also reflect side effects of the treatment that are so serious that the patients choose/have to leave study. However, for simplicity, we will ignore this problem in the latter questions and act as if censoring was independent of the outcome and of the treatment.

The figure obtained via the mice package displays the difference missing patterns. The left numbers correspond to the number of subjects for a specific pattern and the right numbers the number of missing data per pattern. For instance there are 188 subjects with full data and 6 subjects with only baseline data.

5. We can select individual with no missing data at baseline nor at week 52 doing:

```
armd.wideCC <- armd.wide[is.na(armd.wide$visual0)+is.na(armd.wide$visual52)
]==0,]
```

and then compute the change:

```
armd.wideCC$change <- armd.wideCC$visual52 - armd.wideCC$visual0
```

We then obtain a histogram using:

```
gg.dens <- ggplot(armd.wideCC, aes(change, color = treat.f, fill = treat.f))
gg.dens <- gg.dens + geom_histogram(alpha = 0.45, aes(y=..density..),
  position = "identity")
gg.dens <- gg.dens + xlab("\u0394 Y (52)")
gg.dens
```

‘stat_bin()’ using ‘bins = 30’. Pick better value with ‘binwidth’.

6. With a t-test:

```
e.tt <- t.test(change ~ treat.f, data = armd.wideCC)
e.tt
```

Welch Two Sample t-test

```
data: change by treat.f
t = 1.8842, df = 191.47, p-value = 0.06106
alternative hypothesis: true difference in means between group Placebo and group Active is
95 percent confidence interval:
 -0.2013017  8.7949525
sample estimates:
mean in group Placebo mean in group Active
      -11.18095          -15.47778
```

we obtain an estimated effect of:

```
diff(e.tt$estimate)
```

```
mean in group Active  
-4.296825
```

i.e. a faster decrease in vision in the active group. The corresponding p-value and confidence intervals are displayed the output of the t-test object.

We can try to retrieve this result by comparing the change in each group:

```
armd.sum052 <- armd.sum[armd.sum$week %in% c("0","52"),]  
diff.active <- diff(armd.sum052[armd.sum052$treat.f=="Active","mean"])  
diff.placebo <- diff(armd.sum052[armd.sum052$treat.f=="Placebo","mean"])  
c(diff.active,diff.placebo,diff.active-diff.placebo)
```

```
[1] -15.478512 -10.898039 -4.580473
```

We don't get exactly the same result because `armd.sum` was computed on the entire population while the t-test was performed only among those with complete data.

7. When fitting a linear regression using `lm`, we assume that the residual variance is the same in both groups which is not the case with a t-test. If we were to assume same variance when doing a t-test:

```
t.test(change ~ treat.f, data = armd.wideCC, var.equal = TRUE)
```

Two Sample t-test

```
data: change by treat.f  
t = 1.8746, df = 193, p-value = 0.06235  
alternative hypothesis: true difference in means between group Placebo and group Active  
95 percent confidence interval:  
-0.2239352 8.8175860  
sample estimates:  
mean in group Placebo mean in group Active  
-11.18095 -15.47778
```

we would get the same as the linear regression.

8. With the complete case approach we discarded all data from individual who had a missing value at week 52. So even if a subject had full data until week 24, he was not included in the analysis. We have seen that there was a strong correlation between timepoints (e.g. >0.8 between week 24 and 52) so it is not optimal to not exploit early measurements of the outcome.

9. To interpret the coefficients it can be useful:

- to look at graphical display - e.g. see slide 32 of the lecture slides
- to know the reference level:

```
levels(e052.lmm)$reference
```

```
treat.f      week  
"Placebo"    "0"
```

(Intercept)	is the average vision in the control group at week 0.
treat.fActive	is the difference in vision between groups at baseline.
Then week52	is the time effect in the control group.
treat.fActive:week52	is the difference in time effect between groups, i.e. the treatment effect.

The estimate differs (slightly) from part 2 because we now take into account all individuals, and not only those with complete data. This will typically result in a more precise estimate and possibly less bias. So this estimate is more reliable.

10. We can use the formula from slide 34 to deduce the estimated vision at each timepoint:

```
c(placebo.0 = as.double(coef(e052.lmm)[("(Intercept)"])),  
  placebo.52 = sum(coef(e052.lmm)[c("(Intercept)","week52")]),  
  active.0 = sum(coef(e052.lmm)[c("(Intercept)","treat.fActive")]),  
  active.52 = sum(coef(e052.lmm)))
```

```
placebo.0 placebo.52  active.0  active.52  
55.33613  44.24126   54.57851   39.10051
```

We can compare our results with:

```
dummy.coef(e052.lmm)
```

	treat.f	week	estimate	se	df	lower	upper
1	Placebo	0	55.33613	1.366936	238.0491	52.64330	58.02897
2	Active	0	54.57851	1.355592	238.0488	51.90802	57.24900
3	Placebo	52	44.24126	1.770454	205.8764	40.75071	47.73180
4	Active	52	39.10051	1.868344	216.5233	35.41804	42.78298

11. We first gather all relevant quantities:

```
sigma0 <- coef(e052.lmm, effects="variance")["sigma"]
sigma52 <- sigma0*coef(e052.lmm, effects="variance")["k.52"]
rho <- coef(e052.lmm, effects="correlation")["rho(0,52)"]
alpha0 <- coef(e052.lmm)["(Intercept)"]
alpha52 <- alpha0 + coef(e052.lmm)["week52"]
```

and then apply the formula:

```
unname(alpha52 + rho * sigma52/sigma0 * (armd.114$visual[1]-alpha0))
```

```
[1] 37.04983
```

Note that because individual 114 has a baseline value below the baseline mean (and the correlation is positive), its predicted value is below the follow-up mean.

12. First note that the reference group has changed:

```
levels(eLin.lmm)$reference
```

```
week   treat.f
"0"    "Placebo"
```

The `(Intercept)` is the average vision at baseline in the active group. The `week4`, `week8`, `week24`, and `week52` coefficients are the change in vision from baseline in the active group. The `week.num:treat.fPlacebo` is the amount of decrease in vision per week due to the treatment.

With this model we can summarize the treatment effect in this single number as we assume a linear treatment effect (i.e. proportional to the number of weeks from baseline).

This assumption makes it easier to communicate the treatment effect (as it is not time specific) and can also lead to a gain in statistical power if the linearity assumption is reasonable.

13. The interpretation of the first five coefficients (`(Intercept)`, `week4`, `week8`, `week24`, and `week52`) is the same as in the previous model. The coefficient `treat.fActive` is the group difference at baseline while the remaining coefficients (`week4:treat.fActive`, `week8:treat.fActive`, `week24:treat.fActive`, and `week52:treat.fActive`) indicate the difference in change in vision between the two groups (i.e. the treatment effect at each follow-up time).

So the coefficient `week52:treat.fActive` has the same interpretation as the one found in question 9. However its value differs because we use a different model to handle the missing data. Intuitively, we now use values from timepoint 0, 4, 12, 24 (instead of only timepoint 0) to "guess" the missing value. This new estimate should be more precise and less biased.

14. From the graph it seems that we do not miss an important feature of the treatment effect over time by assuming a proportional effect. Note that this assumption enforces that the two group have identical average baseline value, which is reasonable in a randomized study.
- `eFlex.lmm` would be recommended if one is only interested in the long-term treatment effect, as this model makes no assumption on the treatment effect over time. When one is interested in describing the time dynamic of the treatment effect, an approach like `eLin.lmm` can be more useful. Note in between approaches could be considered, e.g. adding non-linear interaction terms such as `I(week.num^2):treat.f`.